Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.78 |
| ▸ | TSHR | P16473 | 4/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.78 |
| ▸ | PGR | P06401 | 3/20 | 0.78 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.78 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desoxycorticosterone SCHEMBL4066 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL25773308 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL15763287 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL28269906 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL21243062 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL13752803 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL18891475 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL9504254 | 0.97 | LMNA (0.94) | LMNASMN1; SMN2CYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL10593143 | 0.96 | LMNA (0.92) | LMNASMN1; SMN2CYP3A4ALDH1A1MAPT | |
| SCHEMBL22732246 | 0.91 | LMNA (0.84) | LMNASMN1; SMN2CYP3A4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11682 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260140124-A1 | PCOS STRATIFICATION | THE UNIVERSITY OF BIRMINGHAM (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260108610-A1 | Drug-Resistant Immune Cells and Methods of Use Thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2026-04-23 | — | — | US | claimed |
| EP-4718074-A2 | MASS SPECTROMETRY ASSAY FOR CONGENITAL ADRENAL HYPERPLASIA | Quest Diagnostics Investments Incorporated (US) | 2026-04-01 | — | — | EP | claimed |
| EP-4718073-A2 | MASS SPECTROMETRY ASSAY FOR CONGENITAL ADRENAL HYPERPLASIA | Quest Diagnostics Investments Incorporated (US) | 2026-04-01 | — | — | EP | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-20260034056-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | ALCON INC (CH) | 2026-02-05 | — | — | US | claimed |
| EP-4673549-A1 | COMPOSITIONS AND METHODS FOR IMPROVED ADENOVIRAL- BASED GENE THERAPY UTILIZING CORTICOSTEROID TREATMENT | Pacira Therapeutics, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-20250312274-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-10-09 | — | — | US | claimed |
| US-20250302742-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-10-02 | — | — | US | claimed |
| US-4443440-A | ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1984-04-17 | — | — | US | claimed |
| EP-0104746-A1 | 21-Hydroxycorticosteroid esters, and compositions containing them | THE UPJOHN COMPANY (US) | 1984-04-04 | — | — | EP | claimed |
| US-4346709-A | Drug delivery devices comprising erodible polymer and erosion rate modifier | ALZA CORPORATION (US) | 1982-08-31 | — | — | US | claimed |
| US-4321208-A | Preparation of directly iodinated steroid hormones and related compounds | SAHADEVAN VELAYUDHAN | 1982-03-23 | — | — | US | claimed |
| EP-0033341-A1 | CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS | Research Corporation (US) | 1981-08-12 | — | — | EP | claimed |
| US-4283394-A | ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION (US) | 1981-08-11 | — | — | US | claimed |
| WO-1981000410-A1 | CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS | RESEARCH CORP (US) | 1981-02-19 | — | — | WO | claimed |
| US-4180570-A | 17β-Hydroxy-4-androsten-3-ones and process for the preparation thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-12-25 | — | — | US | claimed |
| US-4083973-A | ANABOLIC ACTIVITY, NANDROLONE | AKZONA INCORPORATED (US) | 1978-04-11 | — | — | US | claimed |
| US-4080448-A | Method of treating cellular stress | MIRSKY LOUIS H | 1978-03-21 | — | — | US | claimed |